Emergex Vaccines Approved as Member of the Social Stock Exchange

Oxford, UK, 20 February 2017 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact report by the Social Stock Exchange’s independent Admissions Panel.

Emergex aim to offer a novel approach to vaccine development, using 100% synthetic components to activate the immune system; this technology is ideally suited to low resource environments such as the developing world, which are disproportionately affected by pandemics caused by these types of diseases. These vaccines will be used to create a clinical grade international vaccine repository that will act as a first line of defence against existing and newly emerging infectious outbreaks.

The Social Stock Exchange enables its accredited impact issuers to raise capital or undertake primary or secondary listings of debt or equity instruments.


Notes to Editors

About Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity.

Find out more online at www.emergexvaccines.com.

About the Social Stock Exchange
The Social Stock Exchange provides access to the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities. The aim of the exchange is to help these businesses connect with investors and unlock capital at scale. All issuer member companies must meet a rigorous set of criteria before joining, including the publication of an Impact Report.

The Social Stock Exchange has an agreement with NEX Exchange (formerly ISDX) to operate the Social Stock Exchange branded market segment for impact businesses.

The Social Stock Exchange Ltd (FRN: 625231) is an appointed representative of Kession Capital Limited (FRN: 582160) which is authorised and regulated by the Financial Conduct Authority (“FCA”) in the UK.
NEX is a Recognised Investment Exchange operating a regulated market and a growth market and provides a secondary market trading facility. NEX is supervised by the FCA.

For more information, please visit www.socialstockexchange.com.

Media Contacts:

Instinctif Partners
Sue Charles/Eileen Paul//Ashley Tapp/Emma-Jane Humphreys
Phone: +44 (0)20 7457 2020
Email: Emergex@instinctif.com